X

Sign up for Equitymaster's free daily newsletter, The 5 Minute WrapUp and get access to our latest Multibagger guide (2017 Edition) on picking money-making stocks.

This is an entirely free service. No payments are to be made.


Download Now Subscribe to our free daily e-letter, The 5 Minute WrapUp and get this complimentary report.
We hate spam as much as you do. Check out our Privacy Policy and Terms Of Use.
Compare Natco Pharma with Abbott India - Equitymaster
  • MyStocks

MEMBER'S LOGINX

     
Login Failure
   
     
   
     
 
 
 
(Please do not use this option on a public machine)
 
     
 
 
 
  Sign Up | Forgot Password?  

NATCO PHARMA vs ABBOTT INDIA - Comparison Results

ABBOTT INDIA 
   Change

Formerly known as Knoll Pharmaceuticals Limited, Abbott India Limited (AIL) is a subsidiary of Abbott Capital India Limited in which the latter holds about 69% stake. It is involved in the discovery, development, manufacture and marketing of pharmace... More

DO YOU LIKE THESE REPORTS? TELL US!

Current Valuations

    NATCO PHARMA ABBOTT INDIA NATCO PHARMA/
ABBOTT INDIA
 
P/E (TTM) x 33.8 32.8 103.1% View Chart
P/BV x 17.2 8.2 210.1% View Chart
Dividend Yield % 0.7 0.8 81.1%  

Financials

 NATCO PHARMA   ABBOTT INDIA
EQUITY SHARE DATA
    NATCO PHARMA
Mar-14
ABBOTT INDIA
Mar-16
NATCO PHARMA/
ABBOTT INDIA
5-Yr Chart
Click to enlarge
High Rs8776,015 14.6%   
Low Rs4243,707 11.4%   
Sales per share (Unadj.) Rs223.41,236.9 18.1%  
Earnings per share (Unadj.) Rs31.1122.2 25.4%  
Cash flow per share (Unadj.) Rs40.3129.0 31.2%  
Dividends per share (Unadj.) Rs5.0035.00 14.3%  
Dividend yield (eoy) %0.80.7 106.8%  
Book value per share (Unadj.) Rs219.5521.2 42.1%  
Shares outstanding (eoy) m33.0721.25 155.6%   
Bonus/Rights/Conversions PA--  
Price / Sales ratio x2.93.9 74.1%   
Avg P/E ratio x20.939.8 52.6%  
P/CF ratio (eoy) x16.137.7 42.8%  
Price / Book Value ratio x3.09.3 31.8%  
Dividend payout %16.128.6 56.2%   
Avg Mkt Cap Rs m21,504103,296 20.8%   
No. of employees `000NA3.0 0.0%   
Total wages/salary Rs m1,1283,370 33.5%   
Avg. sales/employee Rs ThNM8,891.8-  
Avg. wages/employee Rs ThNM1,140.0-  
Avg. net profit/employee Rs ThNM878.3-  
INCOME DATA
Net Sales Rs m7,38926,284 28.1%  
Other income Rs m167504 33.1%   
Total revenues Rs m7,55626,789 28.2%   
Gross profit Rs m1,7933,665 48.9%  
Depreciation Rs m304144 210.8%   
Interest Rs m3668 4,521.0%   
Profit before tax Rs m1,2904,017 32.1%   
Minority Interest Rs m460-   
Prior Period Items Rs m00-   
Extraordinary Inc (Exp) Rs m00-   
Tax Rs m3091,421 21.7%   
Profit after tax Rs m1,0272,596 39.6%  
Gross profit margin %24.313.9 174.0%  
Effective tax rate %23.935.4 67.7%   
Net profit margin %13.99.9 140.8%  
BALANCE SHEET DATA
Current assets Rs m3,68114,446 25.5%   
Current liabilities Rs m3,1234,725 66.1%   
Net working cap to sales %7.637.0 20.4%  
Current ratio x1.23.1 38.6%  
Inventory Days Days8951 174.1%  
Debtors Days Days5920 300.1%  
Net fixed assets Rs m7,6851,113 690.6%   
Share capital Rs m331213 155.6%   
"Free" reserves Rs m6,67010,808 61.7%   
Net worth Rs m7,25911,076 65.5%   
Long term debt Rs m9550-   
Total assets Rs m11,95716,241 73.6%  
Interest coverage x4.5497.0 0.9%   
Debt to equity ratio x0.10-  
Sales to assets ratio x0.61.6 38.2%   
Return on assets %11.716.0 72.7%  
Return on equity %14.223.4 60.4%  
Return on capital %20.736.3 57.0%  
Exports to sales %39.40.6 6,400.9%   
Imports to sales %5.712.6 45.1%   
Exports (fob) Rs m2,908162 1,799.4%   
Imports (cif) Rs m4213,322 12.7%   
Fx inflow Rs m3,445268 1,285.6%   
Fx outflow Rs m7033,927 17.9%   
Net fx Rs m2,743-3,659 -74.9%   
CASH FLOW
From Operations Rs m1,4402,514 57.3%  
From Investments Rs m-1,089-800 136.2%  
From Financial Activity Rs m-353-803 43.9%  
Net Cashflow Rs m-1912 -0.2%  

Share Holding

Indian Promoters % 52.0 0.0 -  
Foreign collaborators % 1.5 75.0 2.0%  
Indian inst/Mut Fund % 7.8 7.9 99.2%  
FIIs % 16.6 0.1 16,630.0%  
ADR/GDR % 0.0 0.0 -  
Free float % 26.0 17.1 152.0%  
Shareholders   25,395 18,270 139.0%  
Pledged promoter(s) holding % 0.0 0.0 -  
NM: Not Meaningful
Source: Company Annual Reports, Regulatory Filings, Equitymaster

Compare NATCO PHARMA With:   PIRAMAL ENTERPRISES  NOVARTIS  PLETHICO PHARMA  DR. REDDYS LAB  GSK PHARMA  

Compare NATCO PHARMA With:   ADCOCK INGRAM (S. Africa)  MYLAN (US)  ACTAVIS (US)  TEVA PHARMA (Israel)  



Today's Market

Global Markets Remain Volatile Ahead of US Growth Concerns(RoundUp)

Benchmark indices in US corrected marginally by 0.8% during the week. Minutes of Federal Reserve's July meeting are out and the situation looks to be in favor of the emerging markets.

Related Views on News

Sun Pharma: Bottomline Slips into the Red Amidst Challenging Environment (Quarterly Results Update - Detailed)

Aug 14, 2017

A challenging environment and one-time expense pushes Sun Pharma into a loss in the first quarter.

Lupin: Bigger Challenges or Bigger Margin of Safety? (Quarterly Results Update - Detailed)

Aug 14, 2017

GST impact coupled with price erosion in US leads to lower profits for the quarter.

Dr Reddy's: US Pressure Continues to Haunt (Quarterly Results Update - Detailed)

Aug 8, 2017

Profits plunge due to higher raw material costs.

Biocon: Lower Licensing Income Leads to Muted Growth for the Quarter (Quarterly Results Update - Detailed)

Jun 23, 2017

Net Profit lower due to exceptional items in the previous year.

The Power of 5 Minutes (The 5 Minute Wrapup)

Jun 16, 2017

Here's what you can expect from The 5 Minute Wrapup in the coming months and years.

More Views on News

Most Popular

Demonetisation Barely Made Any Difference to Tax Collections(Vivek Kaul's Diary)

Aug 7, 2017

The data tells us quite a different story from the one the government is trying to project.

A 'Backdoor' to Multibaggers: It's Like Investing in Asian Paints Ten Years Ago(The 5 Minute Wrapup)

Aug 10, 2017

Don't miss these proxy bets on growing companies or in a few years you will be looking back with regret.

Should You Invest In Bharat-22 ETF? Know Here...(Outside View)

Aug 8, 2017

Bharat-22 is one of the most diverse ETFs offered so far by the Government. Know here if you should invest...

Signs of Life in the India VIX(Daily Profit Hunter)

Aug 12, 2017

The India VIX is up 36% in the last week. Fear has gone up but is still low by historical standards.

7 Financial Gifts For Your Sister This Raksha Bandhan(Outside View)

Aug 7, 2017

Raksha Bandhan signifies the brother-sister bond. Here are 7 thoughtful financial gifts for sisters...

More

Become A Smarter Investor In
Just 5 Minutes

Multibagger Stocks Guide 2017
Get our special report, Multibagger Stocks Guide (2017 Edition) Now!
We will never sell or rent your email id.
Please read our Terms

NATCO PHARMA SHARE PRICE


Aug 18, 2017 (Close)

TRACK NATCO PHARMA

  • Track your investment in NATCO PHARMA with Equitymaster's Portfolio Tracker. Set live price alerts, get research alerts and more. Get access now...
  • Add To MyStocks

NATCO PHARMA 5-YR ANALYSIS

COMPARE NATCO PHARMA WITH

MARKET STATS